The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.
Glatiramer acetate (GA) is approved for the treatment of multiple sclerosis (MS). However, the mechanism of action of GA in MS is still unclear. In particular, it is not known whether GA can modulate the pro-inflammatory Th17-type immune response in MS. We investigated the effects of original GA (Co...
Main Authors: | Mikhail Melnikov, Svetlana Sharanova, Anastasiya Sviridova, Vladimir Rogovskii, Nina Murugina, Anna Nikolaeva, Yulia Dagil, Vladimir Murugin, Tatiana Ospelnikova, Alexey Boyko, Mikhail Pashenkov |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0240305 |
Similar Items
-
Dopaminergic Receptor Targeting in Multiple Sclerosis: Is There Therapeutic Potential?
by: Mikhail Melnikov, et al.
Published: (2021-05-01) -
The role of glatiramer acetate in the early treatment of multiple sclerosis
by: David W Brandes
Published: (2010-06-01) -
New features of glatiramer acetate for the treatment of remitting multiple sclerosis
by: N. Y. Lasch
Published: (2015-12-01) -
Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
by: Oscar Fernández
Published: (2012-08-01) -
Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
by: Oscar Fernández
Published: (2012-04-01)